Marker Therapeutics, Inc.MRKRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +647.65% | +113.13% | -71.94% | -26.35% | -35.98% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.10% | +2.26% | +24.76% | +56.50% | +87.80% |
| Weighted Average Shares Diluted Growth | +1.10% | +2.26% | +24.76% | +56.50% | +87.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -328.47% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -328.47% |
| Receivables Growth | +793.51% | +128.32% | +32.80% | -32.76% | +123.69% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -44.01% | +28.58% | +20.59% | +26.49% | +99.21% |
| Book Value per Share Growth | -55.90% | +29.15% | -1.46% | -30.91% | +31.44% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +69.73% | +94.33% | +21.76% | +78.86% | -32.42% |
| SG&A Expenses Growth | -39.50% | -25.42% | +12.41% | -17.23% | +19.79% |